The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bioprotect; Isoray
Research Funding - Bioprotect (Inst); Candel Therapeutics (Inst)
Real-world safety and effectiveness of radium-223 (223Ra) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated in the US: The non-interventional REASSURE study.
 
Daniel Y. Song
No Relationships to Disclose
 
Saby George
Consulting or Advisory Role - AVEO; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Merck; Pfizer; QED Therapeutics; Sanofi; Seattle Genetics/Astellas
Research Funding - Agensys (Inst); Aravive (Inst); Aveo (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Sanofi
 
Shawn Zimberg
Honoraria - Bayer; Bioprotect
Consulting or Advisory Role - Boston Scientific
Speakers' Bureau - Bayer; Bioprotect
 
Luke T. Nordquist
No Relationships to Disclose
 
Jeffrey Tomaszewski
No Relationships to Disclose
 
Peter S Conti
Travel, Accommodations, Expenses - GE Healthcare
 
Jeffrey Meltzer
Employment - Bayer
Stock and Other Ownership Interests - Bayer; Bayer (I); Lilly O.; Lilly O. (I); Pfizer; Pfizer (I)
 
Frank Verholen
Employment - Bayer
Travel, Accommodations, Expenses - Bayer
 
Anja Schmall
Employment - Bayer
 
Celestia S. Higano
Employment - CTI BioPharma Corp (I)
Stock and Other Ownership Interests - CTI BioPharma Corp (I)
Consulting or Advisory Role - Abbvie/Pharmacyclics; AstraZeneca; Bayer; Exelixis; Tolmar; Vaccitech
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); eFFECTOR Therapeutics (Inst); Ferring (Inst); Medivation (Inst); Pfizer (Inst); Roche (Inst)
Expert Testimony - Ferring
Travel, Accommodations, Expenses - Bayer
 
A. Oliver Sartor
Stock and Other Ownership Interests - Abbvie; Cardinal Health; Clarity Pharmaceuticals; Clovis Oncology; GlaxoSmithKline; Lilly; Noria Therapeutics; PSMA Therapeutics; United Health Group
Consulting or Advisory Role - Advanced Accelerator Applications; ARTbio; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clarity Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Fusion Pharmaceuticals; Hengrui Therapeutics; Isotopen Technologien; Janssen; Merck; Morphimmune; Myovant Sciences; Myriad Genetics; Noria Therapeutics; Northstar; Novartis; Noxopharm; Pfizer; Point Biopharma; Progenics; Sanofi; Telix Pharmaceuticals; TEmpus; TeneoBio; Tessa Therapeutics; Theragnostics
Research Funding - Advanced Accelerator Applications (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); InVitae (Inst); Janssen; Lantheus Medical Imaging (Inst); Merck (Inst); Progenics; Sanofi (Inst); SOTIO
Patents, Royalties, Other Intellectual Property - Koochekpour, Sartor AO, inventors. Saposin C and receptors as targets for treatment of benign and malignant disorders. US patent awarded January 23, 2007 (patent no. 7,166,691).
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi